Week in Review: Fosun in $2 Billion Bidding War for US Rights to Novartis' Generic Drugs

Deals and Financings

Trials and Approvals

• Innovent Biologics of Suzhou reported strong preliminary results from a China Phase II trial of its PD-1 candidate, in patients with Hodgkin Lymphoma;
• Beijing's BeiGene enrolled the first patient in a China Phase III trial of pamiparib, a PARP inhibitor used as a maintenance therapy in ovarian cancer patients;  
• CStone Pharma of Suzhou dosed the first patient in a Australian Phase I clinical trial of CS1003, a PD-1 candidate aimed at solid tumor cancers;

Government and Regulatory

• China plans to increase patent protection on innovative drug to 25 years, up from the current 20 years, an answer to US tariffs on China goods, following US allegations that China does not observe international IP protection standards.

Stock Symbols: (SHA: 600196; HK: 02196) (NYSE: NVS) (HK: 3320) (SHA: 600750) (HK: 2269) (SHA: 600867) (Paris: ADOC) (SHZ: 300255) (NSDQ: KTOV) (SHZ: 002821) (NSDQ: BGNE)

Share this with colleagues:

More From BioPortfolio on "Week in Review: Fosun in $2 Billion Bidding War for US Rights to Novartis' Generic Drugs"